Bristol-Myers Squibb Company (BMY) Analyst Ratings & Price Targets

Bristol-Myers Squibb Company

BMY · NYSE

Analyst Consensus

Hold

25 analysts

$64

Current

$67

Low

$68

Average

$75

High

Average target implies +6.02% versus the current price.

Analyst Ratings Synthesis

The consensus is Hold, with all 25 tracked analysts in that category. The mean price target is 64.5, while low and high targets are not available, so the target cluster and total spread cannot be determined from the supplied evidence. No named analyst is identified as the most or least bullish. No attributable analyst rating or target revisions were supplied during the week; the reported upward change was Bristol Myers management raising its 2026 outlook, not a documented broker revision. The substantive debate is whether newer-product momentum and pipeline progress can overcome legacy-portfolio declines and justify a value-oriented case, or whether the apparently low valuation reflects durable erosion and execution risk.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Piper Sandler	David Amsellem	Buy Maintained rating and set price target	$75	+16.9%	Jul 28, 2026	Open the report this row came from
B of A Securities	—	Unrated Set price target	$67	+4.5%	Apr 9, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BERENBERG BANK

BMO CAPITAL MKT

CANTOR FITZGERA

CITIGROUP

CO FORECST

DAIWA AMERICA

DEUTSCHE BK SEC

EDWARD JONES

GOLDMAN SACHS

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

RAYMOND JAMES

ROTHSCHILD REDB

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: BMY
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve.

Key Issues

Bullish view

Second-quarter revenue rose 5% year over year to approximately $13 billion because newer products offset declines across the legacy portfolio. Management also highlighted growth-portfolio momentum, supporting the view that the company is transitioning successfully.

Bearish view

The same results confirm that the legacy portfolio is still shrinking, requiring newer medicines to replace established revenue. If growth products do not scale consistently, erosion in older therapies could limit overall performance.

Analyst Consensus

See all

Hold

25 analysts

$64

Current

$67

Low

$68

Average

$75

High

Average target implies +6.02% versus the current price.

Earnings History

BeatMissNo estimate

Bristol-Myers Squibb Company

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers